BioWorld Science

Feb. 12, 2013

View Archived Issues

Boehringer Ingelheim patents new CCR2 receptor antagonists

Read More

Scientists elucidate factors necessary for platelet killing of P. falciparum

Read More

Takeda provides overview of activities from April-December 2012

Read More

Immune responses analyzed in infants administered an enterovirus vaccine

Read More

Bristol-Myers Squibb patents new Y4 receptor agonists

Read More

New PI3Kgamma and delta inhibitors disclosed by Infinity Pharmaceuticals and Intellikine

Read More

Scientists at Theracrine patent novel agents for cancer

Read More

Laboratorios del Dr. Esteve synthesizes novel sigma1-receptor ligands

Read More

Nanjing Molecular Research divulges new agents for HCV infection

Read More

GlaxoSmithKline: fourth quarter 2012 in review

Read More

First-in-human results of LNP-encapsulated siRNA therapy show promise in cancer patients

Read More

Albany Molecular Research out-licenses tubulin inhibitor

Read More

Champions Oncology receives on-time payment under Teva technology collaboration

Read More

TG Therapeutics opens expansion cohorts in trial of ublituximab

Read More

Catabasis Pharmaceuticals reports phase I data for CAT-1004

Read More

Synageva BioPharma begins phase III ARISE trial

Read More

UCB and Amgen decide not to pursue romosozumab program in fracture healing

Read More

Galenica provides update on regulatory processes for PA-21

Read More

Pediatric indication of Ixiaro approved in Europe

Read More

French group synthesizes new imino-sugar derivatives

Read More

Pfizer presents new GPR119 receptor agonists

Read More

Merck KGaA synthesizes novel FSH receptor agonists

Read More

Revlimid approved in China, gets priority review for new indication in U.S.

Read More